96 studies found for:    "Intraocular melanoma"
Show Display Options
Rank Status Study
1 Not yet recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
2 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Suspended Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Liver Metastases;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Biological: ipilimumab;   Radiation: yttrium Y 90 glass microspheres;   Other: laboratory biomarker analysis
4 Completed Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Biological: cixutumumab;   Other: laboratory biomarker analysis
5 Completed Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIA Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: sargramostim;   Biological: tyrosinase peptide;   Other: placebo;   Other: laboratory biomarker analysis
6 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
7 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
8 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Carcinoma of Unknown Primary;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: recombinant flt3 ligand;   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Biological: neoantigen-based melanoma-poly-ICLC vaccine;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Recruiting INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: IDO1 inhibitor INCB024360;   Biological: MELITAC 12.1 peptide vaccine;   Other: laboratory biomarker analysis
10 Recruiting Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
11 Active, not recruiting Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
12 Active, not recruiting
Has Results
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: sorafenib tosylate
13 Completed AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Intraocular Melanoma;   Iris Melanoma;   Lentigo Maligna Malignant Melanoma;   Recurrent Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
14 Active, not recruiting Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Intervention: Drug: vorinostat
15 Active, not recruiting VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ziv-aflibercept;   Other: pharmacological study
16 Active, not recruiting Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Recurrent Intraocular Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Drug: dacarbazine;   Other: laboratory biomarker analysis
17 Recruiting Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
18 Completed Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
Condition: Intraocular Melanoma
Intervention: Drug: nab-paclitaxel
19 Terminated Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
Conditions: Intraocular Melanoma;   Metastatic Cancer
Interventions: Drug: fotemustine;   Drug: isolated perfusion
20 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years